OpenLegislation

Commission Regulation (EU) 2018/1480 of 4 October 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures and correcting Commission Regulation (EU) 2017/776 (Text with EEA relevance)

EU Regulation 2018/1480 · Adopted 4 October 2018 · Extends to United Kingdom

Original text. legislation.gov.uk does not revise this item, so later amendments are not shown here. Changes made to it are listed under each provision when known.

Commission Regulation (EU) 2018/1480

of 4 October 2018

amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures and correcting Commission Regulation (EU) 2017/776

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006f1, and in particular Article 37(5) and Article 53(1) thereof,

Whereas:

(1)

Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.

(2)

Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of the Agency (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete harmonised classification and labelling of certain substances.

(3)

Council Directive 67/548/EECf2 and Directive 1999/45/EC of the European Parliament and of the Councilf3 were repealed with effect from 1 June 2015. As a result, Part 3 of Annex VI to Regulation (EC) No 1272/2008 was amended by Commission Regulation (EU) 2016/1179f4 to remove Table 3.2. That amendment took effect on 1 June 2017. Annex VI to Regulation (EC) No 1272/2008 was further amended by Commission Regulation (EU) 2017/776f5 to delete references to Table 3.2, to convert references to Table 3.1 into references to Table 3 and to delete references to the repealed Directives. Under Article 2(2) of Regulation (EU) 2017/776, the majority of those amendments were to apply from 1 June 2017, while the remaining amendments were stated to apply from 1 December 2018. However, due to an oversight, Article 2(2) failed to list two further amendments that should have applied from 1 June 2017, including in particular the amendment changing the name of the Table from ‘Table 3.1’ to ‘Table 3’. The second subparagraph of Article 2(2) of Regulation (EU) 2017/776 should therefore be corrected to include reference to those two amendments. This correction, although it has the effect of applying the two amendments retroactively, does not affect the rights and obligations of manufacturers, importers, downstream users or suppliers.

(4)

Regulation (EU) 2017/776 also amended Annex VI to Regulation (EC) No 1272/2008 to add harmonised ‘Acute Toxicity Estimate’ (ATE) values in Table 3.1 as part of the information relating to the classification and labelling of certain substances for the purposes of the classification of mixtures. The ATE introduced for nicotine was expressed in mg/kg. In order to clarify how mixtures containing nicotine should be classified, the ATE for the oral and the dermal routes for nicotine should instead be expressed in ‘mg/kg bw’f6. The ATEs for three other substances, namely colecalciferol, 1,2-dihydroxybenzene and pinoxaden should also be expressed in the same way. In addition, in the title of the penultimate column of Table 3.1, a footnote should be added indicating what the abbreviation ‘mg/kg bw’ stands for.

(5)

The Annex to Commission Regulation (EU) 2018/669f7 provides for the translation of the names of the substances included in Table 3.1 of Annex VI to Regulation (EC) No 1272/2008. As a consequence, the title of the second column of that Table, which currently refers to ‘international chemical identifications’, should be amended to take account of the fact that the ‘international chemical identifications’ will lose their international character once the Regulation providing for their translation in Annex VI becomes applicable. For the sake of consistency, this amendment should take effect when the translation of the names in Annex VI takes effect. The new title should reflect the terminology used in Article 18 of Regulation (EC) No 1272/2008.

(6)

Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or revised classifications and to sell existing stocks. That period of time will also be necessary to allow suppliers to adapt to and comply with other legislative obligations resulting from the new or updated harmonised classifications, such as those set out in Article 22(f) or Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Councilf8, those set out in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Councilf9 or those set out in Article 44 of Regulation (EC) No 1107/2009 of the European Parliament and of the Councilf10.

(7)

Regulation (EC) No 1272/2008 should therefore be amended accordingly.

(8)

In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow for new provisions to be applied at an earlier stage on a voluntary basis, suppliers should be allowed to apply the new and updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of those new or updated classifications.

(9)

The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Article 133 of Regulation (EC) No 1907/2006,

HAS ADOPTED THIS REGULATION:

Annotations to the whole text

Footnotes

f1

OJ L 353, 31.12.2008, p. 1.

f2

Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (OJ 196, 16.8.1967, p. 1).

f3

Directive 1999/45/EC of the European Parliament and of the Council of 31 May 1999 concerning the approximation of laws, regulations and administrative provisions of the Member States relating to the classification, packaging and labelling of dangerous preparations (OJ L 200, 30.7.1999, p. 1).

f4

Commission Regulation (EU) 2016/1179 of 19 July 2016 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (OJ L 195, 20.7.2016, p. 11).

f5

Commission Regulation (EU) 2017/776 of 4 May 2017 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (OJ L 116, 5.5.2017, p. 1).

f6

Body weight.

f7

Commission Regulation (EU) 2018/669 of 16 April 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (OJ L 115, 4.5.2018, p. 1).

f8

Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

f9

Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).

f10

Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (OJ L 309, 24.11.2009, p. 1).

Contents

  1. 1Amendment to Regulation (EC) No 1272/2008
  2. 2Correction to Regulation (EU) 2017/776
  3. 3Entry into force and application
  4. Signature
  5. Annex Annex

1Amendment to Regulation (EC) No 1272/2008

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

2Correction to Regulation (EU) 2017/776

In Regulation (EU) 2017/776, the second subparagraph of Article 2(2) is replaced by the following:

‘In the Annex, point (1), point (2) and points (a), (b) and (c) of point (3) shall apply from 1 June 2017.’

3Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

Point (1) and point (a) of point (2) of the Annex shall apply from 1 December 2019.

Points (b), (c), (d) and (e) of point (2) of the Annex shall apply from 1 May 2020.

By way of derogation from the third paragraph of this Article, substances and mixtures may, before 1 May 2020, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.

Signature

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 4 October 2018.

For the Commission

The President

Jean-Claude Juncker

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

  1. (1)

    in Part 1, the heading of point 1.1.1.4 is replaced by the following:

    ‘ Chemical name ’;

  2. (2)

    in Part 3, Table 3.1 is amended as follows:

    1. (a)

      the title of the second column is replaced by the following: ‘Chemical name’;

    2. (b)

      the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*)

      1. (*)

        ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’;

    3. (c)

      the entry corresponding to index number 607-414-00-6 is deleted;

    4. (d)

      the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively:

      Index NoChemical nameEC NoCAS NoClassificationLabellingSpecific Conc. Limits, M-factors and ATEsNotes
      Hazard Class and Category Code(s)Hazard statement Code(s)Pictogram, Signal Word Code(s)Hazard statement Code(s)Suppl. Hazard statement Code(s)
      ‘006-044-00-7

      isoproturon (ISO);

      3-(4-isopropylphenyl)-1,1-dimethylurea

      		251-835-434123-59-6

      Carc. 2

      STOT RE 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H351

      H373 (blood)

      H400

      H410

      GHS08

      GHS09

      Wng

      H351

      H373 (blood)

      H410

      M = 10

      M = 10’

      ‘015-101-00-5

      phosmet (ISO);

      S-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-dimethyl phosphorodithioate;

      O,O-dimethyl-S-phthalimidomethyl phosphorodithioate

      		211-987-4732-11-6

      Repr. 2

      Acute Tox. 4

      Acute Tox. 3

      STOT SE 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H361f

      H332

      H301

      H370 (nervous system)

      H400

      H410

      GHS08

      GHS06

      GHS09

      Dgr

      H361f

      H332

      H301

      H370 (nervous system)

      H410

      M = 100

      M = 100’

      ‘016-096-00-2

      thifensulfuron-methyl (ISO);

      methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate

      		—79277-27-3

      Aquatic Acute 1

      Aquatic Chronic 1

      H400

      H410

      GHS09

      Wng

      		H410

      M = 100

      M = 100’

      ‘017-011-00-1sodium hypochlorite, solution … % Cl active231-668-37681-52-9

      Skin Corr. 1B

      Eye Dam. 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H314

      H318

      H400

      H410

      GHS05

      GHS09

      Dgr

      H314

      H410

      		EUH031

      M = 10

      M = 1

      EUH031:

      C ≥ 5 %

      		B’
      ‘025-002-00-9potassium permanganate231-760-37722-64-7

      Ox. Sol. 2

      Repr. 2

      Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1

      H272

      H361d

      H302

      H400

      H410

      GHS03

      GHS08

      GHS07

      GHS09

      Dgr

      H272

      H361d

      H302

      H410’

      ‘603-180-00-4

      colecalciferol;

      cholecalciferol;

      vitamin D3

      		200-673-267-97-0

      Acute Tox. 2 Acute Tox. 2 Acute Tox. 2

      STOT RE 1

      H330

      H310

      H300

      H372

      GHS06

      GHS08

      Dgr

      H330

      H310

      H300

      H372

      • inhalation:

        ATE = 0,05 mg/L (dusts or mists)

      • dermal:

        ATE = 50 mg/kg bw

      • oral:

        ATE = 35 mg/kg bw

        STOT RE 1; H372: C ≥ 3 %

        STOT RE 2; H373: 0,3 % ≤ C < 3 %’

      ‘604-014-00-3

      chlorocresol;

      4-chloro-m-cresol;

      4-chloro-3-methylphenol

      		200-431-659-50-7

      Acute Tox. 4

      Skin Corr. 1C

      Eye Dam. 1

      STOT SE 3

      Skin Sens. 1B Aquatic Acute 1

      Aquatic Chronic 3

      H302

      H314

      H318

      H335

      H317

      H400

      H412

      GHS07

      GHS05

      GHS09

      Dgr

      H302

      H314

      H335

      H317

      H410

      		M = 1’
      ‘604-016-00-4

      1,2-dihydroxybenzene;

      pyrocatechol

      		204-427-5120-80-9

      Carc. 1Β

      Muta. 2

      Acute Tox. 3

      Acute Tox. 3

      Skin Irrit. 2

      Eye Irrit. 2

      H350

      H341

      H311

      H301

      H315

      H319

      GHS08

      GHS06

      Dgr

      H350

      H341

      H311

      H301

      H315

      H319

      • oral:

        ATE = 300 mg/kg bw

      • dermal:

        ATE = 600 mg/kg bw’

      ‘604-090-00-84-tert-butylphenol202-679-098-54-4

      Repr. 2

      Skin Irrit. 2

      Eye Dam. 1

      Aquatic Chronic 1

      H361f

      H315

      H318

      H410

      GHS08

      GHS05

      GHS09

      Dgr

      H361f

      H315

      H318

      H410

      		M = 1’
      ‘605-003-00-6

      acetaldehyde;

      ethanal

      		200-836-875-07-0

      Flam. Liq. 1

      Carc. 1B

      Muta. 2

      STOT SE 3

      Eye Irrit. 2

      H224

      H350

      H341

      H335

      H319

      GHS02

      GHS08

      GHS07

      Dgr

      H224

      H350

      H341

      H335

      H319’

      ‘606-047-00-92-benzyl-2-dimethylamino-4′-morpholinobutyrophenone404-360-3119313-12-1

      Repr. 1B

      Aquatic Acute 1

      Aquatic Chronic 1

      H360D

      H400

      H410

      GHS08

      GHS09

      Dgr

      H360D

      H410’

      ‘607-096-00-9maleic anhydride203-571-6108-31-6

      Acute Tox. 4

      STOT RE 1

      Skin Corr. 1B

      Eye Dam. 1

      Resp. Sens. 1

      Skin Sens. 1A

      H302

      H372 (respiratory system) (inhalation)

      H314

      H318

      H334

      H317

      GHS07

      GHS08

      GHS05

      Dgr

      H302

      H372 (respiratory system) (inhalation)

      H314

      H334

      H317

      		EUH071Skin Sens. 1A; H317: C ≥ 0,001 %’
      ‘607-103-00-5succinic anhydride203-570-0108-30-5

      Acute Tox. 4

      Skin Corr. 1

      Eye Dam. 1

      Resp. Sens. 1

      Skin Sens. 1

      H302

      H314

      H318

      H334

      H317

      GHS07

      GHS05

      GHS08

      Dgr

      H302

      H314

      H334

      H317

      		EUH071’
      ‘607-113-00-Xisobutyl methacrylate202-613-097-86-9

      Flam. Liq. 3

      STOT SE 3

      Skin Irrit. 2

      Skin Sens. 1B

      H226

      H335

      H315

      H317

      GHS02

      GHS07

      Wng

      H226

      H335

      H315

      H317

      		D’
      ‘607-373-00-4quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate414-200-4200509-41-7

      Carc. 2

      Repr. 2

      Acute Tox. 4

      STOT RE 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H351

      H361fd

      H302

      H373

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H351

      H361fd

      H302

      H373

      H410

      M = 1

      M = 1’

      ‘613-167-00-5reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1)—55965-84-9

      Acute Tox. 2

      Acute Tox. 2

      Acute Tox. 3

      Skin Corr. 1C

      Eye Dam. 1

      Skin Sens. 1A Aquatic Acute 1

      Aquatic Chronic 1

      H330

      H310

      H301

      H314

      H318

      H317

      H400

      H410

      GHS06

      GHS05

      GHS09

      Dgr

      H330

      H310

      H301

      H314

      H317

      H410

      		EUH071

      Skin Corr. 1C; H314: C ≥ 0,6 %

      Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %

      Eye Dam. 1; H318: C ≥ 0,6 %

      Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %

      Skin Sens. 1A; H317: C ≥ 0,0015 %

      M = 100

      M = 100

      		B’
      ‘613-205-00-0propiconazole (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole262-104-460207-90-1

      Repr. 1B

      Acute Tox. 4

      Skin Sens. 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H360D

      H302

      H317

      H400

      H410

      GHS08

      GHS07

      GHS09

      Dgr

      H360D

      H302

      H317

      H410

      M = 1

      M = 1’

      ‘614-001-00-4

      nicotine (ISO);

      3-[(2S)-1-methylpyrrolidin-2-yl]pyridine

      		200-193-354-11-5

      Acute Tox. 2

      Acute Tox. 2

      Acute Tox. 2

      Aquatic Chronic 2

      H330

      H310

      H300

      H411

      GHS06

      GHS09

      Dgr

      H330

      H310

      H300

      H411

      • inhalation:

        ATE = 0,19 mg/L (dusts or mists)

      • dermal:

        ATE = 70 mg/kg bw

      • oral:

        ATE = 5 mg/kg bw’
    5. (e)

      the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1:

      Index NoChemical nameEC NoCAS NoClassificationLabellingSpecific Conc. Limits, M-factors and ATEsNotes
      Hazard Class and Category Code(s)Hazard statement Code(s)Pictogram, Signal Word Code(s)Hazard statement Code(s)Suppl. Hazard statement Code(s)
      ‘604-094-00-X

      isoeugenol; [1]

      (E)-2-methoxy-4-(prop-1-enyl)phenol; [2]

      (Z)-2-methoxy-4-(prop-1-enyl)phenol [3]

      202-590-7 [1]

      227-678-2 [2]

      227-633-7 [3]

      97-54-1 [1]

      5932-68-3 [2]

      5912-86-7 [3]

      		Skin Sens. 1AH317

      GHS07

      Wng

      		H317Skin Sens. 1A; H317: C ≥ 0,01 %’
      ‘607-724-00-12,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin—240494-71-7

      Acute Tox. 4

      Acute Tox. 3

      STOT SE 1

      STOT RE 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H332

      H301

      H370 (nervous system)

      H373

      H400

      H410

      GHS06

      GHS08

      GHS09

      Dgr

      H332

      H301

      H370 (nervous system)

      H373

      H410

      M = 100

      M = 100’

      ‘607-725-00-7isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S-methoprene—65733-16-6

      Aquatic Acute 1

      Aquatic Chronic 1

      H400

      H410

      GHS09

      Wng

      		H410

      M = 1

      M = 1’

      ‘607-726-00-2

      pinoxaden (ISO);

      8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate

      		—243973-20-8

      Repr. 2

      Acute Tox. 4

      Acute Tox. 4

      Eye Irrit. 2

      STOT SE 3

      Skin Sens. 1A

      Aquatic Acute 1

      Aquatic Chronic 3

      H361d

      H332

      H302

      H319

      H335

      H317

      H400

      H412

      GHS08

      GHS07

      GHS09

      Wng

      H361d

      H332

      H302

      H319

      H335

      H317

      H410

      • inhalation:

        ATE = 4,63 mg/L (dusts or mists)

      • oral:

        ATE = 500 mg/kg bw

        M = 1’

      ‘607-727-00-8

      tetramethrin (ISO);

      (1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate

      		231-711-67696-12-0

      Carc. 2

      Acute Tox. 4

      STOT SE 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H351

      H302

      H371 (nervous system) (inhalation)

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H351

      H302

      H371 (nervous system) (inhalation)

      H410

      M = 100

      M = 100’

      ‘607-728-00-3(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate214-619-01166-46-7

      Carc. 2

      Acute Tox. 4

      STOT SE 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H351

      H302

      H371 (nervous system) (inhalation)

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H351

      H302

      H371 (nervous system) (inhalation)

      H410

      M = 100

      M = 100’

      ‘607-729-00-9

      mesosulfuron-methyl (ISO);

      methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)-p-toluate;

      		—208465-21-8

      Aquatic Acute 1

      Aquatic Chronic 1

      H400

      H410

      GHS09

      Wng

      		H410

      M = 100

      M = 100’

      ‘607-730-00-4

      spirodiclofen (ISO);

      3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate

      		—148477-71-8

      Carc. 1B

      Repr. 2

      STOT RE 2

      Skin Sens. 1B

      Aquatic Chronic 1

      H350

      H361f

      H373

      H317

      H410

      GHS08

      GHS07

      GHS09

      Dgr

      H350

      H361f

      H373

      H317

      H410

      		M = 10’
      ‘607-731-00-Xsodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl (EZ)-sulfanilylcarbonimidate; asulam-sodium218-953-82302-17-2

      Skin Sens. 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H317

      H400

      H410

      GHS07

      GHS09

      Wng

      H317

      H410

      M = 1

      M = 1’

      ‘607-732-00-5salicylic acid200-712-369-72-7

      Repr. 2

      Acute Tox. 4

      Eye Dam. 1

      H361d

      H302

      H318

      GHS08

      GHS07

      GHS05

      Dgr

      H361d

      H302

      H318’

      ‘608-068-00-9

      flutianil (ISO);

      (2Z)-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile

      		—958647-10-4Aquatic Chronic 1H410

      GHS09

      Wng

      		H410M = 100’
      ‘612-293-00-8reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine447-920-2-

      Repr. 2

      Acute Tox. 4

      Skin Corr. 1B

      Eye Dam. 1

      H361f

      H302

      H314

      H318

      GHS08

      GHS07

      GHS05

      Dgr

      H361f

      H302

      H314

      		EUH071’
      ‘613-326-00-92-methylisothiazol-3(2H)-one220-239-62682-20-4

      Acute Tox. 2

      Acute Tox. 3

      Acute Tox. 3

      Skin Corr. 1B

      Eye Dam. 1

      Skin Sens. 1A

      Aquatic Acute 1

      Aquatic Chronic 1

      H330

      H311

      H301

      H314

      H318

      H317

      H400

      H410

      GHS05

      GHS06

      GHS09

      Dgr

      H330

      H311

      H301

      H314

      H317

      H410

      		EUH071

      Skin Sens. 1A; H317: C ≥ 0,0015 %

      M = 10

      M = 1’

      ‘613-327-00-4

      pyroxsulam (ISO);

      N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide

      		—422556-08-9

      Skin Sens. 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H317

      H400

      H410

      GHS07

      GHS09

      Wng

      H317

      H410

      M = 100

      M = 100’

      ‘613-328-00-X1-vinylimidazole214-012-01072-63-5Repr. 1BH360D

      GHS08

      Dgr

      		H360DRepr. 1B; H360D: C ≥ 0,03 %’
      ‘616-224-00-2

      amisulbrom (ISO);

      3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide

      		—348635-87-0

      Carc. 2

      Eye Irrit. 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H351

      H319

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H351

      H319

      H410

      M = 10

      M = 10’